Why Don’t We Have Better Alzheimer’s Drugs Yet? | Jack Hidary at Davos 2026 @sandboxaq
Why Don’t We Have Better Alzheimer’s Drugs Yet? | Jack Hidary at Davos 2026  @sandboxaq
Uploaded April 2026 | Updated September 2026, 2 weeks ago
After decades of research, we still don’t have breakthrough treatments for diseases like Alzheimer's disease.

We need AI trained on biology, chemistry, and physics: models that can simulate how drugs behave before they reach human trials.

That’s the promise of large quantitative models (LQMs).

Interview via Anastasios Economou (iGrow) https://www.igrow.vc

Learn more about SandboxAQ's quantitative AI here: sandboxaq.com/solutions/large-quantitative-models

#sandboxaq #lqms
Why Don’t We Have Better Alzheimer’s Drugs Yet? | Jack Hidary at Davos 2026How Natashia Kaur Raina Found Her Path in Quantum ComputingAI Ecosystems, Education, and the Future of Society | Mark Mueller-Eberstein at Davos 2026The State of PQC Migration: Policy, Mandates, and Cryptographic Inventory | RWPQC 2026, Session 3Inside SandboxAQ: Building Frontier Medical TechnologyHow ECG Detects Heart Problems (And Its Biggest Limitation) | Magnetocardiography Explained Part 1/4What Happens When Compute Goes Exponential? | Jack Hidary at the Cures ConferenceAI for Science: The Next Wave of Breakthroughs | Voices of Davos 2026How Investors Think About AI, Data, & the Talent War | Jack Hidary & Brent Hoberman at Davos 2026When work stops feeling like work | Luca Ferrara, fAQ podcastJack Hidary on OpenAI Sora Shutdown, AI Economics & Massive IPO Wave | CNBC Squawk on the StreetEntanglement: Part 2
SandboxAQ |

Why Don’t We Have Better Alzheimer’s Drugs Yet? | Jack Hidary at Davos 2026

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER